/Investor DB

Hatteras Venture Partners — 2015 Investments

6 investments dated 2015 · listed companies and verified rows first · show all

Contego Medicalcontegomedical.cominSeries B · Apr 2015 · $6M✓ verified

Contego Medical develops the Neuroguard IEP System, a 3-in-1 carotid stenting device combining a carotid stent, dilation balloon, and integrated embolic protection with a 40-micron filter to reduce stroke and cognitive impairment from microembolization.

HardwareHealthtechMedical DevicesRaleigh, US

Ravish Sachar(CEO & Founder)Paul Sanders(Chief Operating Officer)

Co-investorsLightstone VenturesAmzak HealthMountain Group CapitalUS Venture Partners

Clearside Biomedicalclearsidebio.cominSeries A · Nov 2015 · $4M

Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.

BiotechHealthtechMedical DevicesAlpharetta, US

Mark Prausnitz(Director)inCharles Deignan(Executive Officer)Glenn Noronha(Executive Officer)inDaniel H. White(Executive Officer, Director)in

BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in

Board seatClay ThorpChristy Shaffer· per SEC Form D

Co-investorsHEALTHCARE ROYALTY PARTNERSMountain Group CapitalSolasta VenturesHatteras

G1 Therapeuticsg1therapeutics.comSeries B · Feb 2015 · $33M

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Board seatClay ThorpChristy Shaffer· per SEC Form D

Co-investorsLumira VenturesMountain Group CapitalRA CapitalSolasta Ventures

PhaseBio Pharmaceuticalsphasebio.comFeb 2015 · $7M

PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.

BiotechHealthtechMedical DevicesMalvern, US

Ashutosh Chilkoti(Director)Joel Sussman(Executive Officer)Jonathan Mow(Chief Executive Officer)in

BoardJames Barrett(Director)Michael Gutch(Director)Justin Klein(Director)

Board seatRobert IngramClay Thorp· per SEC Form D

Co-investorsMountain Group CapitalNew Enterprise Associates (NEA)Johnson & Johnson Innovation – JJDC

Graybuggraybug.visionSeries A · Mar 2015 · $2M
Spyryx BiosciencesinSeries A · May 2015 · $18M

BiotechResearch Triangle Park, US

Andrew Jordan(Executive Officer, Director)John Taylor(Executive Officer, Director, Promoter)Robert Tarran(Director)

BoardDonald Rose(Director)

Co-investors5AM VenturesCanaan Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.